Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

The First Trust Mid Cap Growth AlphaDEX ETF (FNY) made its debut on 04/19/2011, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Mid Cap Growth category of the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...

Markets enter the week on edge as Q2 earnings season kicks off with heavyweight banks and global blue chips. Investors will ...

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade) SA analyst upgrades: NVDA, MAIN, ALB, APP, QBTS, HIMS (Update) Anavex Life Sciences GAAP EPS of -$0.13 beats by $0.02 ...

SO Britain’s second-least worst prince is on manoeuvres. Prince Andrew’s nephew, Harry, has been quietly negotiating behind ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

Bhubaneswar: In view of the self-immolation attempt by a 20-year-old student over alleged sexual harassment at a college in Balasore district on Satur.

We came across a bearish thesis on Hims & Hers on FJ Research’s Substack. As of 3ʳᵈ July, Hims & Hers’s share was trading at ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...